VANCOUVER, British Columbia and SAN FRANCISCO, Feb 12, 2025 – Jade Biosciences, Inc. (“Jade”), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in two upcoming investor conferences in March 2025:
- TD Cowen’s 45th Annual Health Care Conference – March 3-5, 2025, in Boston
- Jefferies Biotech on the Beach Summit – March 11-12, 2025, in Miami
Members of Jade’s management team will also be available for one-on-one investor meetings during both conferences.
For more information or to request a meeting, please contact IR@JadeBiosciences.com.
About Jade Biosciences
Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial expected in the second half of 2025. Jade’s pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit jade-bio.local/ and follow the company on LinkedIn.
Jade Biosciences Contact
Media:
Media@JadeBiosciences.com
Investors:
IR@JadeBiosciences.com